

**Tissue Regenix Group plc**  
(‘Tissue Regenix’, the ‘Company’ or the ‘Group’)

**Change of Adviser**

Tissue Regenix (AIM: TRX), the regenerative medical device company, is pleased to announce the appointment of finnCap Ltd as its Nominated Adviser and Broker with immediate effect.

For more information:

**Tissue Regenix Group plc**  
David Cocke, Chief Financial Officer

[www.tissueregenix.com](http://www.tissueregenix.com)  
Via Wall

**finnCap Ltd (Nominated Adviser and Broker)**  
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance  
Nigel Birks/Harriet Ward - ECM

Tel: +44(0)20 7

**Walbrook PR (Financial PR & IR)**  
Alice Woodings / Lianne Applegarth

Tel: +44(0)20 79  
TissueRegenix@walbroc

**About Tissue Regenix ([www.tissueregenix.com](http://www.tissueregenix.com))**

Tissue Regenix is a leading medical device company in the field of regenerative medicine. The Company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech company that specialises in regenerative medicine and is dedicated to the development of high quality, innovative tissue scaffolds, which can enhance healing opportunities in defects created by trauma and disease. CellRight®'s human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

**AIM Rule 17 Disclosure**

The Company announces the following additional director disclosures pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

**David Cocke**

Regarding the directorship disclosures made in David Cocke's announcement of appointment on 21 January 2021, Packaging Partners LC and NuPak Medical Ltd were announced as previous directorships (within the previous 5 years) when they were current directorships. In addition, David Cocke had been a partner of Talon Medical Ltd within the previous 5 years of his appointment to the Board of Tissue Regenix.

**Jonathan Glenn**

Regarding the disclosures made in Jonathan Glenn's announcement of appointment on 19 January 2016, the Company provides the following updates.

Mr. Glenn's full name was disclosed as Jonathan M Glenn. Mr. Glenn's full legal name is Jonathan Martin Glenn.

In addition to the current directorship of Consort Medical plc ("Consort Medical") that was disclosed at the time of his appointment, Jonathan Glenn was also a director of a number of subsidiaries of Consort Medical, as set out below:

AESICA BC Limited  
AESICA Formulation Development Limited  
AESICA Holdco Limited  
AESICA M1 Limited  
AESICA M2 Limited  
AESICA Queensborough Limited  
AESICA Trustee Company Limited  
Bespak Europe Limited  
Bespak Finance Limited  
Bespak Holdings Limited  
Consort Medical Finance 2010 Limited  
Consort Medical Finance Limited  
Consort Medical Limited  
Integrated Aluminium Components Limited  
Medical House (ASI) Limited  
Medical House Products Limited  
Pharmaron Manufacturing Services (UK) Ltd  
The Medical House Group Limited

The Medical House Group Limited  
The Medical House Limited

**Trevor Phillips**


In addition to the directorship disclosures made in Trevor Phillip's announcement of appointment on 5 January 2021, Trevor Phillips had also held the following directorships within the previous 5 years:  
Vectura Group Limited (previously Vectura Group plc)  
Vectura Limited  
Vectura Delivery Devices Limited

**Shervanthi Homer-Vanniasinkam**

In addition to the disclosures made in Shervanthi Homer-Vanniasinkam's announcement of appointment on 1 June 2016, the following directorships are disclosed:

Directorship held at time of appointment to Tissue Regenix: Holistx Limited

Directorship held within previous 5 years at time of appointment to Tissue Regenix: The Vascular Society



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPFZGFMVMLGFZG